Sitagliptin phosphate monohydrate
- Januvia is available for oral use as film coated tablets containing sitagliptin phosphate monohydrate equivalent to 25, 50 or 100 mg of free base.
- Treatment of type 2 diabetes in adults where physical activity and dietary management has not resulted in adequate glycaemic targets.
- Monotherapy when metformin is considered inappropriate due to intolerance; or
- in combination with other anti-hyperglycaemic agents, including insulin.
For the most up to date PBS therapeutic indications for sitagliptin, please see
- The recommended dose of Januvia is 100 mg once daily, with or without food.
- Renal impairment:
eGFR≥ 30 mL/min/1.73 m to < 45 mL/min/1.73 m , the dose of Januvia is 50 mg once daily. eGFR≥ 15 mL/min/1.73 m to < 30 mL/min/1.73 m or with ESRD(eGFR< 15 mL/min/1.73 m ), including those requiring haemodialysis or peritoneal dialysis, the dose of Januvia is 25 mg once daily. Januvia maybe administered without regard to the timing of dialysis.
- No dosage adjustment is required in this age population.
- Type 1 diabetes - Januvia should not be used to treat type 1 diabetes or diabetic ketoacidosis.
- Pancreatitis - There have been reports of acute pancreatitis with all DPP4 inhibitors. If pancreatitis is suspected, Januvia should be discontinued.
- Renal impairment - Januvia is renally excreted. To achieve plasma concentrations similar to those in those with normal renal function, lower dosages are recommended in patients with eGFR< 45 mL/min/1.73 m, as well those requiring haemodialysis or peritoneal dialysis.
- Gastrointestinal disorders: Constipation.
- Infections and infestations: Pharyngitis.
- Vascular disorders: Hypertension. Gastrointestinal disorders: Acute pancreatitis, including fatal and nonfatal haemorrhagic and necrotising pancreatitis, constipation; vomiting.
- Musculoskeletal and connective tissue disorders: Arthralgia; myalgia; pain in extremity; back pain
- Hypersensitivity to sitagliptin or any of the excipients
The absolute bioavailability of sitagliptin is approximately 87%.
- Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway. Approximately 79%of sitagliptin is excreted unchanged in the urine.
The mean volume of distribution at steady state following a single 100 mg intravenous dose of sitagliptin is approximately 198 litres.
The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).
- Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion.
For more detailed information on this product please consult the product information.